Please assess the completion status of the following clinical trial:

Trial Title: Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* TSH in the ideal reference range (0.4-4.0 milli-international units per liter (mIU/L))~* Planned thyroidectomy for nodular thyroid disease or low-risk differentiated thyroid cancer (\<4cm, no ETE, no expected use of RAI or suppressive levothyroxine therapy)~Exclusion Criteria:~* History of psychiatric illness (major illness as defined by DSM IV: major depression, schizophrenia, mania, etc). Patients prescribed chronic medications for psychiatric illness, those taking benzodiazepines or anti-seizure medication.~* Estrogen therapy that is new within the last 6 weeks or if the dose has been changed within the last 6 weeks~* Positive thyroid antibodies~* Chronic use (\>4 weeks) of concomitant medications that could affect cognition and memory (including sedative hypnotics, selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, Topamax, benzodiazepines, etc.)~* Pregnancy~* Steroid therapy~* Persistent cancer of any type or other major medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- levothyroxine in thyroidectomy patients (Type: None): patients undergoing thyroidectomy for nodular thyroid disease

Based on this trial design, predict the completion outcome and termination type (if applicable).